← All stocks

Xilio Therapeutics, Inc.

XLO Net buying
CIK 0001840233 #4621 in the set updated 21 Sep 2026
Bought (120 mo)
$35.13M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$18.55K
$14.31K on a plan · $0.00 straight out of an exercise
Sold at will
$4.24K
6 of 10 sales
Net
+$35.11M
+$35.12M against sales at will

By person

18 insiders · 26 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Flynn James E
10% owner
$12.40M (2)
+$12.40M
1,143,972
$10.06M
Rock Springs Capital Management LP entity
10% owner
$8.00M (1)
+$8.00M
1,256,472
$11.04M
BAY CITY CAPITAL LLC entity
10% owner
$5.00M (1)
+$5.00M
1,129,490
$9.93M
RiverVest Venture Fund IV, L.P. entity
10% owner
$4.00M (1)
+$4.00M
1,441,444
$12.67M
Atlas Venture Fund XI, L.P. entity
10% owner
$3.00M (1)
$4.24K (6)
+$3.00M
2,754,109
$24.21M
+10,366%
GILEAD SCIENCES, INC. entity
10% owner
$2.20M (2)
+$2.20M
9,105,451
$80.04M
+32.7%
Bain Capital Life Sciences Investors, LLC entity
10% owner
$410.16K (4)
+$410.16K
2,805,413
$24.66M
+1.5%
Shannon James Samuel
Director
$92.04K (3)
+$92.04K
10,000
$87.90K
Russo Rene
PRESIDENT AND CEO
$24.68K (1)
+$24.68K
325,422
$2.86M
+62.2%
Frankenfield Christopher James
Chief Financial Officer
$11.36K (2) scheduled
−$11.36K
24,766
$217.69K
Brennan Kevin M.
SVP, FINANCE AND ACCOUNTING
$2.95K (2) scheduled
−$2.95K
6,371
$56.00K
SV7 Impact Medicine Fund LP entity
10% owner
2,602,264
$22.87M
TAKEDA PHARMACEUTICAL CO LTD entity
10% owner
1,475,121
$12.97M
Merck KGaA
10% owner
680,825
$5.98M
FIL Ltd entity
See Remark 1
218,705
$1.92M
Alexandria Venture Investments, LLC entity
10% owner
166,423
$1.46M
Luptakova Katarina
CHIEF MEDICAL OFFICER
33,250
$292.27K
FMR LLC entity
See Remark 1
4,465
$39.25K

No percentages here. This company's share count has moved by a factor of 9.1 over the window, from 5,782,511 to 52,500,328 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 105
Amendments (4/A) skipped 4
Filings about a different issuer 0
Unreadable filings 0
Joint filings 8
Sales on a Rule 10b5-1 plan 4
Sales straight out of an exercise 0
Sales at will 6
Transactions with no price 0
Shares from compensation/vesting 14,169,866
History held since 25 Oct 2021